Keytruda Proves Effectiveness with Mesothelioma

Immunotherapy drug pembrolizumab (Keytruda) continues to show ground-breaking effectiveness in the treatment of malignant pleural mesothelioma, according to the latest published study.

Mesothelioma specialist Dr. Evan Alley detailed the results earlier this month in The Lancet Oncology.

Alley, chief of hematology and medical oncology at Penn Presbyterian Medical Center, believes pembrolizumab could become an accepted second-line treatment for pleural mesothelioma.

Pembrolizumab is marketed as Keytruda by pharmaceutical giant Merck & Co.

Alley cited the ongoing clinical trial involving 13 research sites covering six countries. The trial, which includes the Abramson Cancer Center at Penn Medicine, evaluates the effectiveness of pembrolizumab for patients with several different advanced malignancies.

https://www.asbestos.com/news/2017/03/31/keytruda-proves-effectiveness-with-mesothelioma/

Leave a Reply